Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BROADEN2: KT-621 in Moderate to Severe Atopic Dermatitis
2025-522370-36-00Phase 2Authorised
- Sponsor
- Kymera Therapeutics
- Start
- Feb 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing KT-621 with Placebo → KT-621 (2 arms). Primary endpoint: Percentage change from baseline to Week 16 in EASI score. Planned start Feb 2026; status: authorised.
02
Drugs
KT-621
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2025-522370-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522370-36-00.